Yamanouchi to Market Aventis’ Peptic Ulcer Drug Amidst Merger Talks
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 43 (Table of Contents)
Published: 4 Jan-2004
DOI: 10.3833/pdr.v2004.i43.842 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Aventis Pharma transferred marketing rights for its gastroduodenal ulcer and gastritis treatment, Maalox®, to Yamanouchi...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS